Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Breast Cancer Therapeutics in Major Developed Markets to 2020
Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs
Publisher: GBI Research
No of pages: 106
Publish Date: Jan 2014
GBI Research, the leading business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs'’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan.
The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
The breast cancer therapeutics market in the eight major markets - The US, The UK, France, Germany, Spain, Italy, Japan and Canada - was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020.
The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%.
Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.
Request for discount at: http://www.reportsandintelligence.com/purchase-enquiry/132442
1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Introduction 92.1 Breast Cancer 92.2 Symptoms 92.3 Epidemiology 102.4 Pathophysiology 112.5 Diagnosis 112.6 Prognosis and Disease Staging 122.6.1 Classification 132.7 Treatment Options 142.7.1 Surgery and Radiation Therapy 142.7.2 Chemotherapy 142.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 152.7.5 Resistance to Pharmacological Therapies 162.7.6 Treatment Guidelines 172.7.7 Measuring the Effectiveness of Treatment 183 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Marketed Products 203.1 Key Marketed Products 203.1.1 Herceptin 203.1.2 Halaven 213.1.3 Avastin 223.1.4 Gemzar 233.1.5 Taxotere 233.1.6 Tykerb 243.1.7 Femara 253.1.8 Aromasin26
3.1.9 Zoladex 263.1.10 Arimidex 27
Table Of Content
3.2 Heat Map for Marketed Products 274 Breast Cancer Therapeutics in Major Developed Markets to 2020 - Pipeline Analysis 294.1 Overall Pipeline 294.2 Pipeline Analysis by Molecule Type 314.3 Pipeline Analysis by Mechanism of Action 334.4 Clinical Trials - Failure Rate 354.5 Clinical Trial Size 374.6 Duration 394.7 Promising Drug Candidates in Pipeline 404.7.1 Buparlisib 40
Get full TOC at: http://www.reportsandintelligence.com/breast-cancer-therapeutics-in-major-developed-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-market/table-of-contents
Visit us at :
Stay With Us:
5933 NE Win Sivers Drive,#205, Portland, OR 97220United States